Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.

Area of Science:

• Bone Biology and Metabolism
• Endocrinology
• Pharmacology

Background:

• Thiazolidinediones (TZDs) are antidiabetic agents linked to bone loss and fractures.
• The precise mechanisms behind TZD-induced bone complications remain unclear.
• Understanding these mechanisms is crucial for patient safety and therapeutic development.

Purpose of the Study:

• To investigate the impact of pioglitazone (PIO) on bone cell differentiation.
• To elucidate PIO's effects on the osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/RANK signaling pathway.
• To determine how PIO influences osteoblastogenesis and osteoclastogenesis.

Main Methods:

• Utilized MC3T3-E1 pre-osteoblastic cells and murine bone marrow monocytes (BMMCs).
• Assessed gene and protein expression of key bone markers (OPG, RANKL, PPARγ, RUNX2, ALP, OCN, RANK, cathepsin K, TRAP) via RT-qPCR, Western blotting, and ELISA.
• Evaluated osteoclast differentiation using TRAP staining and activity assays.

Main Results:

• PIO inhibited osteoblastic differentiation of MC3T3-E1 cells.
• PIO promoted osteoclastic differentiation of BMMCs.
• PIO altered OPG and RANKL expression, suggesting a role in the OPG/RANKL/RANK system.
• PIO upregulated RANKL and PPARγ while downregulating OPG, RUNX2, ALP, and OCN in osteoblasts.

Conclusions:

• Pioglitazone suppresses osteoblastogenesis and enhances osteoclastogenesis.
• PIO's effects on bone metabolism may involve modulation of the OPG/RANKL/RANK system.
• These findings provide mechanistic insights into TZD-associated bone loss.